Abstract
Generation of potent antibodies by a mutation-selection process called affinity maturation is a key component of effective immune responses. Antibodies that protect against highly mutable pathogens must neutralize diverse strains. Developing effective immunization strategies to drive their evolution requires understanding how affinity maturation happens in an environment where variants of the same antigen are present. We present an in silico model of affinity maturation driven by antigen variants which reveals that induction of cross-reactive antibodies often occurs with low probability because conflicting selection forces, imposed by different antigen variants, can frustrate affinity maturation. We describe how variables such as temporal pattern of antigen administration influence the outcome of this frustrated evolutionary process. Our calculations predict, and experiments in mice with variant gp120 constructs of the HIV envelope protein confirm, that sequential immunization with antigen variants is preferred over a cocktail for induction of cross-reactive antibodies focused on the shared CD4 binding site epitope.
Original language | English |
---|---|
Pages (from-to) | 785-797 |
Number of pages | 13 |
Journal | Cell |
Volume | 160 |
Issue number | 4 |
DOIs | |
State | Published - 12 Feb 2015 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2015 Elsevier Inc.
Funding
Financial support provided by the Ragon Institute of MGH, MIT, and Harvard (AKC, SW, MK, KDW, JMF) and the International AIDS Vaccine Initiative (IAVI) through the Neutralizing Antibody Consortium SFP1849 (DRB); NIH grants R01 AI033292 (DRB), and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery grant UM1AI100663 (DRB, AKC). We are grateful to Kevin Kaczorowski and Dariusz Murakowski for helpful discussions and comments.
Funders | Funder number |
---|---|
AKC | |
Neutralizing Antibody Consortium | SFP1849 |
National Institutes of Health | R01 AI033292, UM1AI100663 |
National Cancer Institute | R01CA174795 |
International AIDS Vaccine Initiative | |
Ragon Institute of MGH, MIT and Harvard |